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928 | Chem. Sci., 2017, 8, 928–937ual screening leads to non-metal
chelating metallo-b-lactamase inhibitors†
Guo-Bo Li,ab Martine I. Abboud,a Ju¨rgen Brem,a Hidenori Someya,ac
Christopher T. Lohans,a Sheng-Yong Yang,d James Spencer,e David W. Wareham,f
Michael A. McDonough*a and Christopher J. Schoﬁeld*a
There are no clinically useful inhibitors of metallo-b-lactamases (MBLs), which are a growing problem
because they hydrolyse almost all b-lactam antibacterials. Inhibition by most reported MBL inhibitors
involves zinc ion chelation. A structure-based virtual screening approach combined with NMR ﬁltering
led to the identiﬁcation of inhibitors of the clinically relevant Verona Integron-encoded MBL (VIM)-2.
Crystallographic analyses reveal a new mode of MBL inhibition involving binding adjacent to the active
site zinc ions, but which does not involve metal chelation. The results will aid eﬀorts to develop new
types of clinically useful inhibitors targeting MBLs/MBL-fold metallo-enzymes involved in antibacterial
and anticancer drug resistance.Introduction
One of the most important mechanisms of resistance to b-lac-
tam antibacterials involves their hydrolysis as catalysed by
serine-b-lactamases (SBLs) and metallo-b-lactamases (MBLs)
(Fig. 1).1,2 Although clinically useful inhibitors of the SBLs are
established, there are no such MBL inhibitors.3–7 Inhibitors of
human MBL-fold proteins are also of medicinal interest,
including for the human DNA cross-link repair enzymes SNM1-
A/B, in order to combat resistance to major anti-cancer drugs
such as cisplatin.8,9 To date, almost all reported MBL inhibitors
work via zinc ion chelation (Fig. S1 and S2†).10–13 Development
of new types of MBL-fold enzyme inhibitors that do not work via
metal chelation is presently desirable, in part because this may
enable improved selectivity than (readily) achievable with zincrd, 12 Manseld Road, Oxford, OX1 3TA,
.ac.uk; michael.mcdonough@chem.ox.ac.
Delivery System of Ministry of Education,
niversity, Chengdu, 610041, China
s, New Drug Research Division, Otsuka
o, Kawauchi-cho, Tokushima 771-0192,
rative Innovation Center for Biotherapy,
al School, Sichuan University, Sichuan
Biomedical Sciences Building, University
London School of Medicine and Dentistry,
E1 2AT, UK
ESI) available: All experimental details,
nement statistics, details of chemical
ee DOI: 10.1039/c6sc04524cion chelation. Here we report how a virtual screening approach
combined with NMR ltering, led to the identication of non-
metal chelating inhibitors of the clinically relevant Verona
Integron-encoded MBL (VIM)-2. As revealed by crystallographic,
NMR, and biochemical studies, the new inhibitors bind via
a mode that does not involve direct zinc chelation, but which
may mimic interactions made by intact b-lactam substrates as
they initially bind to VIM-2. VIM-2 is a clinically important
representative of the class B1 MBLs (which also includes the
imipenemase (IMP)-1, and New Delhi MBL (NDM)-1), that have
a broad-spectrum substrate prole that includes penicillins,
cephamycins, cephalosporins, oxacephamycins, and carbape-
nems.14 The B1 subfamily MBLs are di-Zn(II) utilizing enzymes,
with both the Zn1 and Zn2 ions having crucial roles in catalysis,
with respect to b-lactam substrate binding, and hydrolytic water
activation.15–17Fig. 1 Outline mechanisms for (a) serine- (SBL) and (b) metallo-b-
lactamase (MBL) catalysed hydrolysis. Note, in the case of the MBL
variations of this mechanism are possible.
This journal is © The Royal Society of Chemistry 2017
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View Article OnlineWe began by carrying out a virtual screen with VIM-2 for
which several high-resolution (<1.5 A˚) crystal structures are
available.12,18–20 A customized virtual screening method, which
combines molecular docking simulations with a molecular
interaction ngerprints (IFPs)-based ltering approach, was
used to identify compounds that are likely to interact with
catalytically important active site residues including Arg228,
Asn233, Phe61, Tyr67, and Asp120 (using the standard BBL
numbering scheme for class B b-lactamases21) as well as zinc
ions. Eight types of protein-ligand interactions (hydrogen-
bonding donor, hydrogen-bonding acceptor, positively charged,
negatively charged, face-to-face p–p stacking, edge-to-face p–p
stacking, hydrophobic, and metal–ligand interactions) as
dened in our previous work22,23 were used to generate the IFPs
(for details of the virtual screening methods see ESI Experi-
mental section SE. 1 and Fig. S3†). Although our strategy
included the identication of potential zinc ion binding
inhibitors, since we have found experimentally that metal ion
chelation can serve to ‘template’ ligands to the active sites of
metallo-enzymes,24–26 we were particularly interested in the
identication of non-Zn chelating inhibitors. We subsequently
screened selected compounds identied in the virtual screen for
activity against VIM-2 using a uorescence-based assay.27 We
then used ligand-observe 1H Carr–Purcell–Meiboom–Gill
(CPMG) NMR spectroscopy28 to test for binding to both the apo-
VIM-2 and catalytically active di-Zn(II) VIM-2, with the aim of
establishing whether the zinc ions are required for inhibitor
binding.
Results
Application of the virtual screening method led to the identi-
cation of a number of fragment-sized compounds, mostly con-
taining acidic groups, that are likely to interact with catalytically
important active site features, replicating interactions involved
in binding the carboxylate present in b-lactam antibacterials
(i.e. with Arg228, Fig. S4–S6†). Of the 20 experimentally tested
compounds, 15 exhibited inhibitory activity against VIM-2, and
8 compounds manifested IC50 values <400 mM, including
compounds 6, 7, 12, 13, 16, 17, 18, and 20 (Table 1 and Fig. S7†).
Using the same assay conditions, we observed that L-captopril
inhibits VIM-2 with an IC50 value of 1.6 mM. As negative
controls, we tested four compounds which did not pass the IFP
score cut-oﬀ in the virtual screen at 2 mM against VIM-2 (44–47,
Fig. S6, Table S4†); these compounds displayed substantially
weaker inhibition than those with IFP scores above the cut-oﬀ.
Since some of the compounds, e.g. 6, 7, 12, 13, 16, 17, 18, and
20, possess potential metal-chelating motifs, further VIM-2
inhibition assays at three diﬀerent concentrations of Zn(II)
(0 mM, 1 mM, and 100 mM) were employed to investigate the
potential for metal chelation in solution. With the exception of
compound 18, no obvious diﬀerences between the inhibitory
activity with or without excess Zn(II) were observed, suggesting
that most of these compounds were not strong Zn(II) chelators
in solution (Fig. S8†). L-Captopril was used as a positive control
for active site/metal binding18 and showed IC50 values of 1.9 mM,
1.6 mM, and 1.4 mMat concentrations of 0 mM, 1 mM, and 100 mMThis journal is © The Royal Society of Chemistry 2017Zn(II), respectively. Compound 18, however, likely causes inhi-
bition, at least in part, by chelating Zn(II) in solution, so
sequestering it from the enzyme.
With the aim of identifying compounds that bind (at least,
substantially) without active site Zn(II) chelation, we used 1H
CPMG NMR (ESI Experimental section SE. 4†) to investigate
binding to catalytically active di-Zn(II) VIM-2 as well as to the
apo-VIM-2 form for selected compounds from the virtual screen
(including 6, 7, 12, 13, 16, 17, and 18). Notably, for 16 and 17,
which displayed the most potent VIM-2 inhibition (IC50 values
of 10.6 mM and 32.8 mM, respectively, Table 1), we observed
binding to both the di-Zn(II) VIM-2 and apo-VIM-2 protein by 1H
CPMG NMR analyses (Fig. 2a and b). For comparison, we
selected a known inhibitor of the VIM-2 MBL, L-captopril, which
works via an established binding mode that involves direct zinc
chelation as revealed by crystallographic analyses;18,29 consis-
tent with its reported mode of binding, we observed that
L-captopril displays strong binding to di-Zn(II)-VIM-2, but only
very weak binding to apo-VIM-2 (Fig. S9†). The reduction in
signal intensity observations with 16 and 17 suggest that they
bind more tightly to di-Zn(II) than apo-VIM-2 (Fig. 2), possibly
reecting the more ordered structure of the di-Zn(II) enzyme.
Overall, these results show that 16 or 17 can bind to VIM-2 in
the absence of zinc ions. However, the presence of zinc indi-
rectly participates in the binding of these inhibitors to VIM-2,
possibly through protein stabilisation, bridging interactions or
a combination thereof. We also observed that 6 (IC50 ¼ 111 mM)
displays strong binding to both di-Zn(II) VIM-2 and apo-VIM-2
(Fig. S10†), indicating that, like 16 and 17, 6 may bind without
metal chelation. In contrast, 12 (IC50 ¼ 87 mM) and 13 (IC50 ¼
135 mM) displayed strong binding to di-Zn(II) VIM-2, but weak
binding to the apo-VIM-2 protein (Fig. S11 and S12†), suggest-
ing that these compounds inhibit VIM-2 by a mode directly
involving zinc chelation. For 7 and 18, for which assays showed
VIM-2 inhibition (IC50 values of 199 mM and 117 mM, respec-
tively, Table 1), we observed binding to both di-Zn(II)- and apo-
VIM-2 (Fig. S13 and S14†) by NMR. In contrast to 16 and 17 (see
below), 12 and 13, which may be metal-chelating VIM-2 inhib-
itors as observed in the inhibition assays and NMR studies
(Table 1, Fig. S11 and S12†), displayed broad-spectrum inhibi-
tion against almost all the tested class B MBLs (Fig. S21†).
In order to investigate the inhibitory mechanism of 16 and
17, we then sought to obtain crystal structures for complexes of
VIM-2 with them (ESI Experimental section SE. 5 and Table S1†
for details of crystallization and structure determinations). Co-
crystallisation experiments yielded structures of VIM-2 in
complex with 16 (1.40 A˚) and 17 (1.93 A˚) (Table S2†). VIM-2:16
and VIM-2:17 crystallized in the P21221 and P212121 space
groups (Table S2†), respectively, with one molecule in the
asymmetric unit (ASU); these space groups diﬀer from those
previously reported for VIM-2.12,18,19 In both structures, there
was clear Fo  Fc density in the VIM-2 active site, into which 16
and 17 could be condently modelled (Fig. S17†). The crystal
structures reveal that 16 and 17 both bind adjacent to the zinc
ions of VIM-2, but in a mode which does not involve direct zinc
chelation (Fig. 3a–c), consistent with the NMR results (Fig. 2a
and b). All of the atoms of the inhibitor are >4 A˚ from the zincChem. Sci., 2017, 8, 928–937 | 929
Table 1 Chemical structures and inhibitory potencies against VIM-2 of
compounds identiﬁed by virtual screening
Cpd IDa Chemical structure IC50 (mM)/pIC50/s.e. log IC50
b
1 637/3.20/0.063
2 993/3.00/0.064
3 >1600/<2.8/—
4 557/3.25/0.135
5 >1600/<2.8/—
6 111/3.95/0.121
7 199/3.70/0.060
8 >1600/<2.8/—
9 439/3.36/0.072
10 >1600/<2.8/—
11 1110/2.96/0.043
12 87/4.06/0.167
13 135/3.87/0.111
14 669/3.18/0.107
15 >1600/<2.8/—
16 10.6/4.98/0.119
17 32.8/4.48/0.055
18 117/3.93/0.104
19 718/3.14/0.212
Table 1 (Contd. )
Cpd IDa Chemical structure IC50 (mM)/pIC50/s.e. log IC50
b
20 292/2.54/2.26
L-Captopril 1.6/5.80/0.02
a Compounds 2, 4, 10, 11, 14, and 15 were tested as stereomeric
mixtures. b The method for measuring IC50/pIC50 (n $ 3) values is
described in ESI methods;27 IC50 curves are given in Fig. S7.
930 | Chem. Sci., 2017, 8, 928–937
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View Article Onlineions (Fig. 3c). The predicted binding modes of 16 and 17 are
similar to those observed in the crystal structures (Fig. S18†),
indicating that the virtual screening method, which searched
for compounds likely to interact with catalytically important
active site features, is a useful strategy for identication of new
MBL-fold enzyme inhibitors.
The crystal structures reveal that 16 and 17 have very similar
binding modes, in which the 3-oxoisoindoline-4-carboxylate
heterocyclic core is positioned to make hydrophobic and elec-
trostatic interactions with the VIM-2 active site features,Fig. 2 1H CPMG NMR analyses reveal that compounds 16 and 17 bind
to both di-Zn(II) and apo-VIM-2 MBL. Binding studies of 16 (a) and 17
(b) to di-Zn(II)-VIM-2 and apo-VIM-2 by 1H CPMG NMR analyses. 16
and 17 bind to both di-Zn(II) and apo-VIM-2 as indicated by signal
intensity reduction in the presence of VIM-2. Assay mixtures contained
50 mM enzyme (either di-Zn(II) VIM-2 in the presence of 50 mM Zn(II) or
apo-VIM-2), and 50 mM of the compound of interest buﬀered with 50
mM Tris-D11, pH 7.5, in 90% H2O and 10% D2O. Black stars denote
imidazole in the di-Zn(II)-VIM-2 buﬀer (Fig. S15†). Note, the 1H NMR
spectra of 16 and 17 in DMSO-D6 (Fig. S16†) are diﬀerent from those in
50 mM Tris-D11, pH 7.5, in 90% H2O and 10% D2O.
This journal is © The Royal Society of Chemistry 2017
Fig. 3 Crystallographic analyses reveals compound 16 and 17 bindingmodes to VIM-2. (a) View from a crystal structure of VIM-2 in complex with
compound 16 (PDB ID 5LE1) reveals that the inhibitor binds to form hydrophobic and electrostatic interactions with residues on the L3 and L10
loops (e.g., p–p stacking interactions with Phe61, and hydrogen-bonding interactions with Asn233; see Fig. S19† for further details of binding
interaction). (b) View from a crystal structure of VIM-2 in complex with 17 (PDB ID 5LCA) reveals that 17 binds via a similar modewith that of 16. (c)
Comparison of complex structures of VIM-2:16 and VIM-2:17 shows that both bind adjacent to zinc ions of VIM-2, but in a mode which does not
involve direct zinc chelation. Distances between the oxygen atoms of the carboxylate of 16 and 17 and Zn2 are 4.63 A˚ and 5.57 A˚, respectively. (d)
The water molecule W3 is positioned to form tight hydrogen-bonding interactions with His196, Tyr224, and Asn233, and is important for binding
the carboxylate of 16 and 17.
Edge Article Chemical Science
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View Article Onlineincluding via p–p stacking interactions with Phe61 on the L3
loop, hydrogen-bond interactions with Arg228 and Asn233 on
the L10 loop and water molecules (such as W3) (Fig. 3a and
b and S19†). 16 (IC50 ¼ 10.6 mM) appears positioned to make
stronger hydrogen-bonding interactions with Arg228 (2.9 A˚),
Asn233 (2.8 A˚), and a water molecule W2 (2.7 A˚) (Fig. 3a and
b and S19†) than 17 (IC50 ¼ 32.8 mM), which may, in part,
explain why it inhibits more potently. As revealed by analysis of
the Cambridge Structural Database, zinc–ligand coordination
bond lengths are generally less than 2.5 A˚,30 thus 16 and 17 both
do not directly chelate the VIM-2 active site zinc ions. A struc-
tural water molecule, W3, also observed in other crystal struc-
tures of VIM-2,12,18–20 is positioned to form hydrogen-bonding
interactions with His196 (2.9 A˚), Tyr224 (2.7 A˚), and Asn233 (2.7
A˚) and appears to be important to the binding of the carboxylate
groups of 16 and 17 (Fig. 3d).This journal is © The Royal Society of Chemistry 2017We then tested 16 and 17 against; the subclass B1 enzymes
VIM-5, VIM-1, NDM-1, SPM-1, and BcII; the subclass B2 enzyme
Cph-A; the subclass B3 enzyme L1; and the class A serine
b-lactamase TEM-1 using our previously established screening
platform27 to investigate their selectivity proles (see ESI
Experimental section SE. 3 and Table S3†). Notably, 16, and to
a greater extent, 17 have considerable selectivity for VIM-2
(Fig. 4a and b). Even for VIM-5, which is a close homolog of VIM-
2 (sequence identity is 89.85%, Fig. S20a†),31,32 16 and 17
showed lower inhibitory activities with IC50 values of 47.6 mM
(10.6 mM for VIM-2) and >400 mM (32.8 mM for VIM-2), respec-
tively (Fig. 3a and b and Table 2). As observed by crystallog-
raphy, the active site features of VIM-2 (PDB 4BZ3)18 and VIM-5
(PDB 5A87)32 are highly similar with only three residues being
diﬀerent (Ile223VIM-2/Val223VIM-5, Tyr224VIM-2/Leu224VIM-5, and
Glu225VIM-2/Ala225VIM-5) on the L10 loop (Fig. S20†). TheseChem. Sci., 2017, 8, 928–937 | 931
Fig. 4 Compounds 16 and 17mimic interactionsmade by substrates. Selectivity proﬁles of 16 (a) and 17 (b) for class B MBLs and the class A serine
b-lactamase TEM-1 (for which no inhibition was observed). (c) Comparison of VIM2 structures in complex with 16 (PDB ID 5LE1) and 17 (PDB ID
5LCA) with that of a representative substrate intermediate of a hydrolysed cephalosporin in complex with NDM-1 (PDB ID 4RL0)33 indicates that
16 and 17 have related binding modes to the cephalosporin substrate. Docking studies imply the binding modes of 16 and 17 may mimic the
binding mode of the substrate prior to b-lactam hydrolysis (Fig. S22†).
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View Article Onlinesubstitutions may contribute to the small diﬀerences observed
by crystallography in the conformations of the L10 loops of VIM-
2 and VIM-5 (Fig. S20b†); however, diﬀerences in solution may
be larger. Notably, a water molecule positioned similarly to W3
in VIM-2 (W3VIM-2), which we propose is important for binding
of 16 and 17 (Fig. 3a–c), is apparent in the VIM-5 active site
(W3VIM-5, Fig. S20b†); however, W3VIM-5 appears to be not so
stable as W3VIM-2 (PDB 5A87). These diﬀerences may explain
why 16 and 17 manifest substantial selectivity for VIM-2 over
VIM-5 (Fig. 4).
We were attracted by the resemblance of the 3-oxoisoindo-
line-4-carboxylate scaﬀold to that of the bicyclic b-lactam MBL932 | Chem. Sci., 2017, 8, 928–937substrates, e.g. cephalosporins (Fig. 1 and 4c). Using molecular
docking analyses, we observed that the bicyclic core of a ceph-
alosporin (a representative bicyclic b-lactam substrate) is likely
to form hydrogen-bonding interactions with Asn233 and the
water molecule W3 (Fig. S22a†), in a similar manner to the 3-
oxoisoindoline-4-carboxylate scaﬀold of 16 and 17, as observed
by our crystallographic analyses (Fig. S22b†). As shown in
Fig. 4c, 16 and 17 also have a similar binding mode to that
observed in a complex of NDM-1 with a ring-opened cephalo-
sporin intermediate;33 the carboxylate groups of 16 and 17 are
positioned to make electrostatic interactions with Arg228 in an
analogous manner to that observed for the binding of theThis journal is © The Royal Society of Chemistry 2017
Table 2 Structure–activity relationships of 3-oxoisoindoline-4-carboxylate derivatives for VIM-2, VIM-5, and VIM-1
Cpd IDa R1 R2
IC50 (mM)/pIC50/s.e. log IC50
b
VIM-2 VIM-5 VIM-1
16 –H 10.6/4.98/0.119 47.6/4.32/0.079 >400/<3.4/—
17 –H 32.8/4.48/0.055 >400/<3.4/— >400/<3.4/—
21 –H 349/3.46/0.15 >400/<3.4/— >400/<3.4/—
22 –H >400/<3.4/— >400/<3.4/— >400/<3.4/—
23 –H 250/3.60/0.17 >400/<3.4/— >400/<3.4/—
24 –H 47.1/4.33/0.037 127/3.90/0.075 >400/<3.4/—
25 –H 320/3.50/0.096 >400/<3.4/— >400/<3.4/—
26 –H >400/<3.4/— >400/<3.4/— >400/<3.4/—
27 –H 176/3.76/0.079 >400/<3.4/— >400/<3.4/—
28 –H 168/3.78/0.153 >400/<3.4/— >400/<3.4/—
29 –H 229/3.64/0.062 >400/<3.4/— >400/<3.4/—
30 –H 17.8/4.75/0.039 >400/<3.4/— >400/<3.4/—
31 –H 133/3.88/0.056 >400/<3.4/— >400/<3.4/—
32 –H 39.3/4.41/0.029 >400/<3.4/— >400/<3.4/—
33 –H 74.0/4.13/0.057 >400/<3.4/— >400/<3.4/—
34 –H 60.3/4.22/0.093 >400/<3.4/— >400/<3.4/—
35 –H 7.7/5.11/0.071 >400/<3.4/— >400/<3.4/—
36 –H 153/3.82/0.138 180/3.75/0.116 >400/<3.4/—
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 928–937 | 933
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Table 2 (Contd. )
Cpd IDa R1 R2
IC50 (mM)/pIC50/s.e. log IC50
b
VIM-2 VIM-5 VIM-1
37 –H 68.1/4.17/0.079 >400/<3.4/— >400/<3.4/—
38 –H >400/<3.4/— >400/<3.4/— >400/<3.4/—
39 –H 71.9/4.14/0.082 >400/<3.4/— >400/<3.4/—
40 –H >400/<3.4/— >400/<3.4/— >400/<3.4/—
41 24.6/4.61/0.097 285/3.49/0.133 >400/<3.4/—
42 20.3/4.69/0.032 348/3.46/0.210 >400/<3.4/—
43 >400/<3.4/— >400/<3.4/— >400/<3.4/—
a Compounds 28, 29, 38, 41, 42, and 43 were tested as racemic mixtures. b The method for measuring IC50/pIC50 (n $ 3) values is described in ESI
methods.27
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View Article Onlinecephalosporin C-4 carboxylate to Lys224 (a structurally equiva-
lent residue to Arg228) of NDM-1 (ref. 33) (Fig. 4c).
On superimposing the crystal structures of VIM-2:16, VIM-
2:17, and di-Zn(II) VIM-2, we observe that the L3 loop of VIM-2
appears closer to the zinc ions when 16 and 17 are bound to
VIM-2 (3.50 A˚ and 3.81 A˚ movements of the C-a atoms of Asp62,
respectively, Fig. S23a†), whilst the L10 loop is positioned
further away from the zinc ions (1.39 A˚ and 1.53 A˚ diﬀerence in
the C-a atom of Asn233, respectively, Fig. S23†). These results
support the proposal that, at least in some cases, these loops
contribute to the highly eﬃcient nature of MBL catalysis by
capturing potential substrates and delivering them to the zinc
ion containing active site for hydrolysis.
From the results above, we propose that the 3-oxoisoindo-
line-4-carboxylate scaﬀold of 16 and 17 is an important factor
contributing to the inhibitory potency and the selectivity for
VIM-2. We carried out structure–activity relationship (SAR)
studies using commercially available and synthesised 3-oxoi-
soindoline-4-carboxylate derivatives with diﬀerent indole-N-
substituents (R1) and/or C-1 substituents (R2) (compounds 21–
43 in Table 2). We synthesized 34 and 35 via the routes in ESI
methods SE. 2 and Scheme S1.† Compared to the hit
compound 16 identied in initial screening (IC50 ¼ 10.6 mM),
which has a 2-chloro-6-uorobenzyl moiety at the R1 position,
compounds 21–29 with diﬀerent substituted-benzyl moieties934 | Chem. Sci., 2017, 8, 928–937at the R1 position exhibited lower inhibitory activities against
VIM-2. The results indicated that chloro- and uoro-substitu-
ents at the ortho position of the N-benzyl group are important
in binding. The VIM-2:16 complex structure implies that the
uorine and chlorine atoms of 16 are likely positioned to form
halogen-bonding interactions with Asn233 (2.88 A˚), and Trp87
(3.41 A˚), and Asp120 (3.34 A˚), respectively (Fig. 3a and S19a†).
Compounds bearing substituted phenyl moieties at the R1
position (30–35) displayed better VIM-2 inhibitory activities
than 21–29, some having comparable activity to 16 and 17.
Compound 30 is more potent than 17 (IC50 ¼ 32.8 mM) with an
IC50 value of 17.8 mM, although its N-phenyl group is unsub-
stituted. As revealed by subsequent crystallographic analyses
of VIM-2 complexes, 30 and 17 have similar binding modes
(Fig. 5a and b and 3b). However, compared with 17, 30 is
apparently better positioned to interact with the Asn233 side
chain (the triuoromethyl group of 17 hinders hydrogen
bonding interactions between the Asn233 side chain and the 3-
oxoisoindoline-4-carboxylate, Fig. 5b and S24†). Compound 35
(IC50 ¼ 7.7 mM), which contains a 3-uoro-4-hydroxyphenyl
motif at its R1 position, was more potent against VIM-2 than
compounds 16 and 17 (Table 2). As observed by crystallog-
raphy, 35 has the same overall binding mode as 30 (Fig. 5c and
d); compared with 30, 35 is positioned to make additional
hydrogen-bonding interactions with Asp119 (3.03 A˚), as well asThis journal is © The Royal Society of Chemistry 2017
Fig. 5 Crystallographic analyses reveals how the 3-oxoisoindoline-4-carboxylate derivatives bind to the VIM-2 MBL. (a) View from a crystal
structure of VIM-2 in complex with 30 (PDB ID 5LCF). (b) Comparison of structures of VIM-2:17 and VIM-2:30 reveals the Asn233 side chain is
unable to form hydrogen-bonds with the 3-oxoisoindoline-4-carboxylate of 17 due to its triﬂuoromethyl group, whichmay explain why 17 is less
potent than 30 (Table 2). (c) View from a crystal structure of VIM-2 in complex with 35 (PDB ID 5LM6). (d) Comparison of VIM-2:30 and VIM-2:35
complex structures reveals 30 and 35 have the same bindingmode. (e) View from a crystal structure of VIM-2 in complex with 42 (PDB ID 5LCH).
(f) Comparison of structures of VIM-2:30 and VIM-2:42 reveals evidence for ﬂexibility in the conformation of Tyr67 and Phe61 on the L3 loop,
suggesting Tyr67 and Phe61 may play important roles in capturing substrates and delivering them to the zinc ions for hydrolysis.
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View Article Onlinehalogen-bonding interactions with Asn233 (3.75 A˚) (Fig. 5c and
d and S25†). In addition to various substituted-benzyl/phenyl
groups, compounds 36–40, containing thiophen-2-ylmethyl,
cyclopentyl, tetrahydrofuran-2-yl, phenethyl, and 3-methox-
ypropyl at R1 position, respectively, were tested. These
compounds displayed only moderate inhibitory potencies
against VIM-2. 41 and 42, which both have an allyl group at the
R2 position, showed relatively good inhibitory activities
against VIM-2 with IC50 values of 24.6 mM and 20.3 mM,
respectively (Table 2). As observed in a VIM-2:42 complex
crystal structure, the allyl group of 42 is positioned to make
hydrophobic interactions with Phe61 and Tyr67 (Fig. 5e and
S26†).
Notably, comparison of structures of VIM-2:30 and VIM-2:42
reveals evidence for exibility in the conformation of the L3
loop, suggesting that Tyr67 and Phe61 may be important in
substrate/inhibitor capture (Fig. 5f). 43 showed much lower
inhibitory potency, supporting the proposed role of the
3-oxoisoindoline-4-carboxylate motif in binding/inhibition. For
VIM-5 and VIM-1, almost all the tested 3-oxoisoindoline-4-
carboxylate derivatives (except 16, 24, and 36) displayed low
inhibitory activities, indicating that the 3-oxoisoindoline-4-
carboxylate scaﬀold is an important factor (along with its
precise substitution pattern) in determining selectivity for VIM-This journal is © The Royal Society of Chemistry 20172. Together, these results led us to conclude that the 3-oxoi-
soindoline-4-carboxylate derivatives selectively inhibit the VIM-
2 MBL via a mode which does not involve direct chelation with
zinc ions.
Discussion
The overall results clearly reveal the potential of a customized
virtual screening approach targeting specic active site features
for the identication of hit compounds for MBL/MBL-fold/
metallo-enzymes. We successfully used an NMR-based
approach employing di-Zn(II)- and apo-VIM-2 to identify hits
from virtual screening that bind to both the apo- and the di-
Zn(II) containing enzymes, hence are less likely to inhibit solely
via direct zinc ion coordination. Indeed, the approach led to
some compounds which bind via direct zinc ion chelation and
some which do not, e.g. 16 and 17, as supported by subsequent
crystallographic analyses.
The combined biophysical analyses reveal 3-oxoisoindoline-
4-carboxylate derivatives as a new class of MBL inhibitor, which
do not, at least with the analysed compounds, strongly chelate
the active site zinc ions. MBL selectivity proling analyses
showed 3-oxoisoindoline-4-carboxylate derivatives can be highly
selective for VIM-2, even with respect to very closely relatedChem. Sci., 2017, 8, 928–937 | 935
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View Article Onlinevariants, e.g. VIM-5. The apparently narrow selectivity of the
3-oxoisoindoline-4-carboxylate derivatives may limit their use
for potentiating b-lactam antibacterials, since clinically useful
MBL inhibitors should be broad spectrum targeting multiple
MBL types, at least the B1 subclass. However, the limited SAR
results presented here suggest that increasing the potency and
broadening the spectrum of the 3-oxoisoindoline-4-carboxylate
inhibitors towards clinically relevant MBLs should be possible.
Most importantly, the results reveal that non-metal-chelating
inhibitors present a route to new types of selective MBL-fold
enzyme inhibitors. This may be particularly useful in targeting
human MBL-fold enzymes involved in cancer drug resistance,8,9
e.g.where highly selective inhibition is desirable. When coupled
with appropriate assays, such selective inhibitors may be useful
in proling clinically observed MBL variants.
From amechanistic perspective, the biophysical analyses are
of interest because the crystallographically observed binding
modes for the 3-oxoisoindoline-4-carboxylate inhibitors, to
some extent, mimic those of intact b-lactam substrates to MBLs.
In this regard, the interactions of the 3-oxoisoindoline-4-
carboxylate inhibitors with the L3/L10 loops are of particular
interest, since it is possible, at least in some cases, that these
loops may contribute to the highly eﬃcient nature of MBL
catalysis by capturing potential substrates and delivering them
to the zinc ion containing active site for hydrolysis.
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